FilingSEC EDGAR8-K
Biomea Fusion Announces Phase 1 Results for BMF-650
· SEC accepted
StagePhase 1
Filing content
The company reported Phase 1 clinical trial results for its oral GLP-1 receptor agonist BMF-650, demonstrating weight reduction and favorable tolerability, and plans to seek strategic partnerships for further development.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…